The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug.
The Sunovion product, Kynmobi, is a formulation of apomorphine... Read more »
HotSpot Therapeutics set out two years ago to find new ways to address elusive disease targets. It now has molecules on the path to becoming potential medicines backed by a fresh... Read more »
The human gut hosts a hub of activity spanning the immune system, the nervous system, and more. But drugging this nexus comes with challenges. Applied Molecular Transport is developing biologic drugs... Read more »
One of the risks to a newborn’s life comes from the mother’s immune system. It attacks the platelets of the fetus, depleting these blood-clotting cells and risking uncontrollable bleeding in the... Read more »
Moderna’s experimental COVID-19 vaccine is showing signs it can elicit antibodies at levels comparable to those found in the blood of dozens of patients who have recovered from the infectious disease,... Read more »
ADC Therapeutics is making its public markets debut, raising about $233 million six months after the cancer drug developer withdrew its initial IPO plans.
Not only did Épalinges, Switzerland-based ADC... Read more »
Legend Biotech, a cancer cell therapy developer with roots in China, is preparing for a US stock exchange listing as its lead candidate keeps pace in the race for a multiple... Read more »
It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells... Read more »
Bristol Myers Squibb’s bid to win FDA approval for its multiple myeloma cell therapy has hit a detour. The FDA declined to review the experimental treatment and has instead asked the... Read more »
Pliant Therapeutics has a pipeline of experimental fibrosis treatments and a research alliance with Novartis. Now the biotech is preparing an IPO to raise cash to advance its clinical-stage programs.
In... Read more »
An experimental MyoKardia drug developed to treat an inherited cardiovascular condition that restricts blood flow is showing it can improve on the symptoms of this condition as well as the heart’s... Read more »
[Updated, 5/11/2020, 10:03 a.m. See below.] Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted... Read more »
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that... Read more »
Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did.
On Thursday evening, Ayala... Read more »
As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday,... Read more »
The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in... Read more »
Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding.
According to financial terms announced Tuesday, Boston-based Alexion... Read more »
The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that... Read more »
If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to... Read more »
Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut.
Late Thursday, Lyra offered 3.5 million shares... Read more »